# AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer

> **NCT03986541** · — · COMPLETED · sponsor: **University of Leeds** · enrollment: 541 (actual)

## Conditions studied

- Colorectal Cancer Stage IV

## Interventions

- **DIAGNOSTIC_TEST:** Immunohistochemistry

## Key facts

- **NCT ID:** NCT03986541
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-07-22
- **Target enrollment:** 541 (ACTUAL)
- **Last updated:** 2024-05-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03986541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03986541, "AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03986541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*